A Multicenter, Open-Label Phase 2 Study of the Safety and Activity of Lenvatinib (E7080) in Subjects With KIF5B-RET-Positive Adenocarcinoma of the Lung
Phase of Trial: Phase II
Latest Information Update: 11 Oct 2016
At a glance
- Drugs Lenvatinib (Primary)
- Indications Adenocarcinoma; Lung cancer
- Focus Therapeutic Use
- Sponsors Eisai Co Ltd
- 11 Oct 2016 Status changed from active, no longer recruiting to completed according to the results presented at the 41st European Society for Medical Oncology Congress.
- 11 Oct 2016 Results presented at the 41st European Society for Medical Oncology Congress.
- 06 Oct 2016 According to an Eisai media release, data from the study was presented at the European Society for Medical Oncology (ESMO) 2016.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History